It has been suggested that ticagrelor monotherapy may in fact offer advantages over DAPT (Warner, Armstrong et al. 2010) and 2 trials including ACS patients after the very early period are currently in progress (National Institutes of Health 2014, National Institutes of Health 2015). However, given the fact that aspirin still possesses some antiplatelet effect in the presence of potent P2Y12 inhibition, its total omission may not prove to be the optimum strategy in higher risk patients, particularly given the current lack of evidence in patients rather than healthy individuals.